The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy (Q38168953)

30 August 2017

The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy (English)

1 reference

30 August 2017

1 reference

François Ghiringhelli

series ordinal

1

object named as

François Ghiringhelli

0 references

Lionel Apetoh

series ordinal

2

object named as

Lionel Apetoh

0 references

publication date

5 December 2013

1 reference

Expert Review of Clinical Immunology

30 August 2017

1 reference

30 August 2017

10

1 reference

30 August 2017

19-30

1 reference

30 August 2017

1

1 reference

Chemotherapy-induced immunosuppression

30 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Calreticulin exposure dictates the immunogenicity of cancer cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Immunogenicity of anthracyclines: moving towards more personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Cardiac glycosides exert anticancer effects by inducing immunogenic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Dynamic regulation of FoxP3 expression controls the balance between CD4+ T cell activation and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Therapeutic targeting of myeloid-derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Immune effects of 5-fluorouracil: Ambivalence matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

SOCS3 transactivation by PPARγ prevents IL-17-driven cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

The Yin and Yang of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Negative regulation of T-cell function by PD-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Tim-3, a negative regulator of anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2014.865520

10.1586/1744666X.2014.865520

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24308838